The Developmental Biology and Solid Tumor Program (DBSTP) brings together 30 members, including 26 Full and four Associate (junior mentored) Members from nine departments with the shared goal of improving outcomes for children and adolescents with solid tumors. In 2009, the Program underwent a change in leadership, prompted by the departure from the SJCCC of Dr. Peter Houghton (then co-leader of the Program). At that time, the SJCCC took the opportunity to reinvigorate the Program, undertaking a collaborative restructuring process that resulted in a translational research pipeline that integrates basic, translational and clinical research. The Program is now structured around three highly-integrated focus groups: (i) The Basic Research Group: This group employs developmental biology and genomic approaches to better understand the processes regulating normal development and how these processes are deregulated in childhood solid tumors. This group also includes an innovative drug discovery and drug development effort to advance molecular-targeted therapies relevant to pediatric solid tumors (ii) Translational Research Group: The translational research group provides an essential bridge between the basic and clinical research groups and is focused on the development and implementation of innovative new methods for testing therapeutics in preclinical models to guide clinical trial development. Investigators in the translational research group have expertise in pharmacokinetics and pharmacodynamics, animal models of pediatric solid tumors, and statistical design of preclinical and clinical trials, (iii) The Clinical Research Group: conducts cutting-edge clinical trials for patients with solid tumors and participates in national collaborative clinical trials through the Children's Oncology Group (COG) and other consortia. The DBSTP is supported by $6.0 million in cancer-focused grants ($4.7 million peer-reviewed, $1.3 million non-peer reviewed), and research in the program has led to 465 publications during the funding period of which 22% (n=102/465) represent intraprogrammatic collaborations, and 29% (n= 136/465) represent interprogrammatic collaborations.

Public Health Relevance

Solid tumors account for 30% of all childhood cancer deaths. Despite improvements in therapy, progress in age-adjusted mortality trends have become stagnant over the past 20 years. Outcomes for children with recurrent or metastatic solid malignancies are particularly poor. The DBSTP, together with the unique resources and collaborations available across the Cancer Center, is working to develop new therapies for these childhood cancers and reduce late effects for survivors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-39
Application #
9439720
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
ElInati, Elias; Russell, Helen R; Ojarikre, Obah A et al. (2017) DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line. Proc Natl Acad Sci U S A 114:12536-12541
Gibson, Todd M; Li, Zhenghong; Green, Daniel M et al. (2017) Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 26:1705-1713
Scott, Daniel C; Hammill, Jared T; Min, Jaeki et al. (2017) Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase. Nat Chem Biol 13:850-857
Patel, Y T; Daryani, V M; Patel, P et al. (2017) Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. CPT Pharmacometrics Syst Pharmacol 6:305-314
Penkert, Rhiannon R; Jones, Bart G; H├Ącker, Hans et al. (2017) Vitamin A differentially regulates cytokine expression in respiratory epithelial and macrophage cell lines. Cytokine 91:1-5
Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2017) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer :
Talleur, Aimee C; Triplett, Brandon M; Federico, Sara et al. (2017) Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Hapl Biol Blood Marrow Transplant 23:1910-1917
Wu, Jianrong (2017) Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model. Stat Biopharm Res 9:25-34
Svolos, P; Reddick, W E; Edwards, A et al. (2017) Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. AJNR Am J Neuroradiol 38:1235-1241
Lin, Wenwei; Goktug, Asli N; Wu, Jing et al. (2017) High-Throughput Screening Identifies 1,4,5-Substituted 1,2,3-Triazole Analogs as Potent and Specific Antagonists of Pregnane X Receptor. Assay Drug Dev Technol 15:383-394

Showing the most recent 10 out of 6607 publications